Abstract 1720P
Background
On February 6, 2023, an earthquake occurred in Turkey that affected 11 provinces, many hospitals and millions of people. In Hatay, one of the provinces most affected by the earthquake, all 4 oncology centers in were partially or completely destroyed. So, a new unit was established in Dörtyol District Hospital, one of the few standing hospitals. On February 27, 2023, the first oncologist was assigned to the new oncology unit in Dörtyol Hospital. On 01 March 2023, the oncology outpatient clinic started to work and with the arrival of drugs, the first intravenous systemic anticancer treatment was administered on 03 March 2023. The aim of this abstract is to share our experience on how oncology services continue in the event of a major disaster.
Methods
In this abstract, the attempts made to provide oncology services after the earthquake in Hatay and the results of the first 100 patients followed in the new facility are summarized. The patients followed at the oncology outpatient clinic had their age, gender, primary diagnosis, and causes for admission retrospectively analysed.
Results
Between 01 and 10 March 2023, 100 patients applied to the oncology unit. A total of 62 of the patients were women. The median age of the group was 54. The most common diagnosis was breast cancer (N=46), followed by GIS (N=17) and lung (N=14) malignancies. The numbers of local, locoregional and metastatic diseases were 20, 33 and 47, respectively. Most common admission purpose was routine follow up (N=38), followed by scheduled systemic therapy (N=34). A total of 38 patients received systemic therapy while 9 had hormonotherapy and 3 had palliative treatment. Respectively, 5 patients were referred to different cities for PET scan, 3 patients for radiotherapy, and 7 patients due to the absence of drugs in the hospital.
Conclusions
Oncology is not a suitable field to delay or cancel active or palliative treatments. For this reason, it is inevitable to continue oncological services under all conditions, as has been seen in the recent COVID pandemic. On the other hand, due to the treatments applied, oncology centers have to meet some basic requirements in terms of infrastructure and work force. As in the Hatay experience, it is vital to take quick actions and ensure coordination after a disaster.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1716P - Addressing clinical trial disparities in Spain: A digital solution
Presenter: Max Hardy-Werbin
Session: Poster session 23
1717P - Management of patients during a digital healthcare record system transition: A phase I unit experience
Presenter: Lyra Del Rosario
Session: Poster session 23
1718P - Impact of the economic status of the patient's country of residence on the outcome of oncology clinical trials
Presenter: Saki Nishiyama
Session: Poster session 23
1719P - Decentralized clinical trials: Is there a space in Italy?
Presenter: Celeste Cagnazzo
Session: Poster session 23
1721P - Self-assessment tool and best-practice sharing to support hospitals in improving the quality of multi-disciplinary teams in lung cancer care
Presenter: Ernest Nadal
Session: Poster session 23
1722P - Factors contributing to differences in evidence compliance rate in cancer treatment among second opinion cases
Presenter: Tomomi Sanomachi
Session: Poster session 23
1723P - Improving access to molecular tumour boards for complex genomic profiles: A healthcare policy from the Netherlands
Presenter: Sahar van Waalwijk van Doorn-Khosrovani
Session: Poster session 23
1724P - Improving access to breast cancer diagnosis and treatment through navigation: Evaluation of a one-year pilot project in Botswana
Presenter: Ariane Migeotte
Session: Poster session 23
1725P - Genetic counselling for cancer in EU member states: Review and foundation for consensus recommendations
Presenter: J. Matt McCrary
Session: Poster session 23
1726P - Optimizing oncology drug spending in a cancer centre in Ireland
Presenter: Ruth Kieran
Session: Poster session 23